Interferon alpha-2b + ribavirin

Drug Profile

Interferon alpha-2b + ribavirin

Alternative Names: Cotronak + interferon alpha-2b; Rebetol® + Intron A®; Rebetron; Rebetron combination therapy™; Ribavirin/interferon alpha-2b

Latest Information Update: 18 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Schering-Plough
  • Developer Merck & Co
  • Class Antivirals; Interferons; Ribonucleosides
  • Mechanism of Action Interferon alpha stimulants; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatitis C
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
  • 25 Oct 2004 The CHMP has recommended extending the use of interferon-α-2b + ribavirin to the treatment of chronic hepatitis C in children over 3 years in the EU
  • 23 Jan 2004 REBETOL® oral solution for use in combination with interferon-α-2b (INTRON® A) injection for the treatment of chronic hepatitis C in patients 3 years and older has been launched in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top